Boston Scientific's Ultraflex
This article was originally published in The Gray Sheet
Executive SummaryEsophageal stent system for the "palliative treatment of advanced esophageal cancer" is approved by FDA. Constructed of Elastalloy, "a highly flexible titanium-based mesh," Ultraflex is inserted in the esophagus "to exert a constant, gentle force that helps keep the passage open" despite obstructive tumors. The firm is promoting the device as superior to rubber or plastic stents, which are "poorly tolerated in half of all patients"
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.